GenSight Biologics S.A. is a clinical-stage biotechnology company specializing in gene therapies for neurodegenerative retinal diseases and central nervous system disorders. Its mission centers on preserving or restoring vision in patients with severe inherited eye conditions through innovative platforms like Mitochondrial Targeting Sequence (MTS) and optogenetics. The lead candidate, LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, targets Leber Hereditary Optic Neuropathy (LHON) caused by ND4 mutations and is in Phase III development, with plans for a pivotal RECOVER trial. Another key asset, GS030, is in Phase I/II trials (PIONEER) for retinitis pigmentosa, demonstrating early efficacy in enabling blind patients to locate objects via optogenetic approaches. Headquartered in Paris, France, with a small team of around 13-16 employees, GenSight Biologics advances mutation-agnostic treatments administered via single intravitreal injections, holding license agreements with institutions like Sorbonne Université and Inserm. Founded in 2012, it plays a pivotal role in ophthalmology biotech, pushing gene therapy toward commercialization for unmet needs in retinal degeneration.